Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intracranial CArtography of Cortical Contribution to Respiratory Load Compensation in Epilepsy (ICARE)

13 mei 2026 bijgewerkt door: Hospices Civils de Lyon

30% of patients with epilepsy suffer from drug-resistant seizures and have a greater risk of premature mortality than the general population. Among all causes of death, the most frequent is SUDEP, for sudden and unexpected death in epilepsy patients. SUDEP typically occurs after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase. Most of patients with drug-resistant seizures demonstrate transient peri-ictal apnea and hypoxemia especially in the aftermath of a GCS. Experimental and clinical data suggest that most SUDEP primarily result from a fatal seizure-related respiratory arrest 5. Apnea was the primary cause of death in several epilepsy models. In patients whose SUDEP had occurred during long-term video-EEG monitoring, we observed fatal postictal central apnea after a nocturnal GCS in all SUDEP. Accordingly, it is currently hypothesized that in a subgroup of patients, repetition of seizures may contribute to chronic alteration of respiratory regulation which may increase the risk of fatal postictal central respiratory arrest.

Central regulation of autonomic function is ensured by the so-called Central Autonomic Network (CAN), which anatomy in humans has primarily been investigated in neuroimaging studies or using intraEEG (iEEG) data in patients with drug-resistant focal epilepsy undergoing presurgical evaluation with intracerebral electrodes. Central regulation of breathing primarily rely on brainstem, especially the preBötzinger complex for rhythm generation and the retrotrapezoid nucleus and dorsal raphe for chemoreception, especially ventilatory response to hypercapnia. However, through an intricated structures connecting these regions, this respiratory signal projects to a network of cortical and subcortical regions mainly including the limbic and sensorimotor cortical areas. Studies in patients undergoing iEEG reinforced the role of limbic and paralimbic structures, with transient central apnea elicited by direct electrical stimulation of amygdala, hippocampus, anterior parahippocampal, and antero-mesial fusiform gyri. However, our group also reported transient hypoxemia could be elicited by cortical direct electrical stimulation outside the temporo-limbic structures, most commonly after stimulation of the perisylvian cortex. Importantly, our group recently showed that involvement of this perisylvian cortex in the epileptogenic zone is a strong risk factor of SUDEP, reinforcing the importance of further studying its integration in the cortical control of respiration.

The involvement of cortical control of ventilation is particularly important to ensure expiratory load compensation, a typical situation after GCS, which is associated with airway obstruction, especially when the face is positioned into the pillow. This cortical component of the physiological response to experimental expiratory loads was investigated in healthy subjects through the study of EEG activity during an expiratory load compensation protocol. Accordingly, EEGs were processed by ensemble averaging expiratory time-locked segments and examined for pre-expiratory EEG potentials, defined as a slow negative shift from the baseline signal preceding expiration, and suggestive of cortical preparation of expiration. Expiratory load compensation was associated with EEG premotor potential presumably involving the supplementary motor area. However, because of the limited spatial resolution of scalp EEG, the organization of cortical neural sources involved in this expiratory load compensation or during response to hypercapnia, especially the interaction between the premotor cortex, the sensorimotor cortical areas and the perisylvian cortex is unknown.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

20

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Rhone
      • Bron, Rhone, Frankrijk, 69500
        • Service de Neurologie Fonctionne et d'Epileptologie Hôpital Neurologique Pierre WERTHEIMER
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study
  2. Aged 18 to 55 years old
  3. Diagnosis of drug-resistant focal epilepsy, as defined by the International League Against Epilepsy 20
  4. Patients undergoing SEEG as part of presurgical evaluation
  5. At least one SEEG electrode localized in the perisylvian cortex
  6. At least one SEEG electrode localized in the premotor cortex

Exclusion Criteria:

1. Ongoing or chronic respiratory and/or cardiac insufficiency and/or ischemic cardiac disease 2. History of stroke in the last 5 years 3. Intracranial hypertension related to space-occupying lesion in the brain 4. Pregnant, parturient, or breastfeeding women 5. Individuals receiving psychiatric care 6. Individuals deprived of their liberty by judicial or administrative decision 7. Adults subject to legal protection measures (guardianship, curatorship) 8. Individuals not affiliated with a social security scheme or beneficiaries of a similar scheme

-

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Patients with drug-resistant epilepsy

Patients with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, who undergo SEEG as part of presurgical evaluation of epilepsy.

In addition to SEEG monitoring, the following procedures will be carried out as part of the research:

  • Comprehensive respiratory monitoring
  • Cardio-respiratory monitoring
  • Expiratory load compensation
  • Hypercapnic challenge
  • Questionnaires completion.
Patients will be recruited among adult patients suffering from drug-resistant focal epilepsy who undergo SEEG monitoring at the Epilepsy Department of the Neurological Hospital. The study will be offered to patients during the hospitalization.
In addition to SEEG monitoring, all participants will undergo comprehensive respiratory monitoring in order to collect respiratory data (tidal volume, VE, and respiratory rate) and gas exchange (PETO2 and PETCO2).
In addition to SEEG channels, cardio-respiratory monitoring consisting of pulse oximetry, respiratory efforts (thoracic and abdominal) and EKG recordings will be performed.
Expiratory load compensation will be assessed in the patient's room in the epilepsy monitoring unit. Patients will breathe through a facemask connected in series to a bidirectional pneumotach and a three-way T-shaped valve. The second port on the three-way valve will be open to room air, and third port will be connected to a CE-marked PEEP valve (PEEP 20 valve, Ambu A/S Denmark) allowing to adjust airflow resistance during expiration from 0.15-2.0 kPa (1.5-20 cmH2O). Respired air will be continuously sampled at the mouth and analyzed for fractional concentrations of O2 and CO2.
The patient breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the patient breathes ambient air and his or her breathing is measured. Then, after a few minutes, the patient is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
Caffeine intake Self-report the degree of "breathlessness" during Expiratory load compensation using a visual analogue scale Self-report the degree of "breathlessness

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cortical localization of pre-expiratory potentials (via SEEG) during HETL (20 cmH₂O) in drug-resistant epilepsy
Tijdsspanne: Through study completion, an average of 1 year
Localization of SEEG contacts will use the anatomical MRI images performed in clinical routine. Pre-expiratory potentials are defined as a slow negative shift from the baseline signal starting between 2 and 0.5 s before the onset of expiration. Both visual and statistical analyses will be used to conclude on the presence of significant pre-expiratory potentials over each recording contact, using the same approach as the one our group used in the past in another physiological paradigm.
Through study completion, an average of 1 year

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
dentification of cortical SEEG contacts showing pre-expiratory potentials under 10 cmH₂O low expiratory threshold load (LETL) in drug-resistant epilepsy
Tijdsspanne: Through study completion, an average of 1 year
Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.
Through study completion, an average of 1 year
Cortical localization of SEEG contacts exhibiting pre-expiratory potentials during a hypercapnic challenge (HyperCO₂) in patients with drug-resistant epilepsy.
Tijdsspanne: Through study completion, an average of 1 year
Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.
Through study completion, an average of 1 year
Latency (ms) of the pre-expiratory potentials in each condition (HETL, LETL, HyperCO2)
Tijdsspanne: Through study completion, an average of 1 year
Through study completion, an average of 1 year
Value of hypercapnic ventilatory response (HCVR)* in each condition (HETL, LETL, HyperCO2)
Tijdsspanne: Through study completion, an average of 1 year
HCVR measures the increase in minute ventilation (VE) induced by an increase of PETCO2 and is a marker of central chemoreception
Through study completion, an average of 1 year
Number of focal to bilateral tonic-clonic seizures during the 18 months preceding the SEEG
Tijdsspanne: Inclusion visit
SUDEP typically occurs after a nocturnal seizure , and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS) , suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase.
Inclusion visit
Localization of the SEEG contacts included in the epileptogenic zone (EZ)
Tijdsspanne: Inclusion visit
The EZ corresponds to cortical regions that directly contribute by their abnormal synchronization to seizure initiation and which surgical removal would be required to result in seizure freedom. Its identification, which is the main medical of SEEG monitoring for presurgical evaluation, combines the analysis of all data collected during the SEEG (inter-ictal, seizures and direct electrical stimulations).
Inclusion visit
Current and past mean daily intake of caffeine (mg/day)
Tijdsspanne: Inclusion visit
Current usual caffeine intake and the one over the last ten years will be assessed by a validated self-survey filled-in at home by the patient and, if needed, the help of the caregiver filled between the inclusion visit and the hospitalization.
Inclusion visit
Respiratory discomfort of the experiment during each condition (HETL, LETL, HyperCO2)
Tijdsspanne: Immediately after the respiratory challenges.
The degree of "respiratory discomfort" will be self-assessed by the subjects on a visual analog scale (VAS) . The subjects were asked to set the cursor on a 10-cm horizontal line, between the descriptions "no respiratory discomfort" on the left and "intolerable respiratory discomfort on the right.
Immediately after the respiratory challenges.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 september 2026

Primaire voltooiing (Geschat)

1 oktober 2028

Studie voltooiing (Geschat)

1 oktober 2028

Studieregistratiedata

Eerst ingediend

6 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 mei 2026

Eerst geplaatst (Werkelijk)

20 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

13 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren